Leslie J. Dickmann, Ph.D. - Publications

2003 University of Washington, Seattle, Seattle, WA 
Pharmaceutical Chemistry

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Shatz W, Hass P, Mathieu M, Kim HS, Leach K, Zhou M, Crawford Y, Shen A, Wang K, Chang DP, Maia M, Crowell S, Dickmann L, Scheer J, Kelley RF. Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed Through Rabbit Studies Using a Species-Matched Fab. Molecular Pharmaceutics. PMID 27244474 DOI: 10.1021/acs.molpharmaceut.6b00345  0.56
2016 Foti RS, Isoherranen N, Zelter A, Dickmann LJ, Buttrick BR, Diaz P, Douguet D. Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1. The Journal of Pharmacology and Experimental Therapeutics. PMID 26937021 DOI: 10.1124/jpet.116.232637  0.56
2013 Smith CL, Arvedson TL, Cooke KS, Dickmann LJ, Forte C, Li H, Merriam KL, Perry VK, Tran L, Rottman JB, Maxwell JR. IL-22 regulates iron availability in vivo through the induction of hepcidin. Journal of Immunology (Baltimore, Md. : 1950). 191: 1845-55. PMID 23836059 DOI: 10.4049/jimmunol.1202716  0.56
2013 Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1598-609. PMID 23792813 DOI: 10.1124/dmd.113.052225  0.56
2013 Konopnicki CM, Dickmann LJ, Tracy JM, Tukey RH, Wienkers LC, Foti RS. Evaluation of UGT protein interactions in human hepatocytes: effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes. Archives of Biochemistry and Biophysics. 535: 143-9. PMID 23562620 DOI: 10.1016/j.abb.2013.03.012  0.56
2013 Wang Z, Lin YS, Dickmann LJ, Poulton EJ, Eaton DL, Lampe JW, Shen DD, Davis CL, Shuhart MC, Thummel KE. Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 1101-16. PMID 23212742 DOI: 10.1002/jbmr.1839  0.56
2013 Dickmann LJ, Isoherranen N. Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 270-4. PMID 22815312 DOI: 10.1124/dmd.112.047118  0.56
2012 Dickmann LJ, VandenBrink BM, Lin YS. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1263-7. PMID 22531045 DOI: 10.1124/dmd.112.044909  0.56
2012 Dickmann LJ, Patel SK, Wienkers LC, Slatter JG. Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Current Drug Metabolism. 13: 930-7. PMID 22475267 DOI: 10.2174/138920012802138642  0.56
2012 Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, Slatter JG. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. Biochemical Pharmacology. 83: 1682-9. PMID 22425536 DOI: 10.1016/j.bcp.2012.03.001  0.56
2012 Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Molecular Pharmacology. 81: 498-509. PMID 22205755 DOI: 10.1124/mol.111.076356  0.56
2011 Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1415-22. PMID 21555507 DOI: 10.1124/dmd.111.038679  0.56
2009 Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. Biochemical Pharmacology. 77: 258-68. PMID 18992717 DOI: 10.1016/j.bcp.2008.10.012  0.56
2008 Tai G, Dickmann LJ, Matovic N, DeVoss JJ, Gillam EM, Rettie AE. Re-engineering of CYP2C9 to probe acid-base substrate selectivity. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1992-7. PMID 18606741 DOI: 10.1124/dmd.108.022186  0.56
2008 McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ. Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1322-31. PMID 18420780 DOI: 10.1124/dmd.108.021261  0.56
2008 Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF, Isoherranen N. Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy. Biochemical Pharmacology. 75: 1677-87. PMID 18342837 DOI: 10.1016/j.bcp.2008.01.012  0.56
2008 Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 38: 264-80. PMID 18274956 DOI: 10.1080/00498250701802514  0.56
2007 Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA. Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chemical Research in Toxicology. 20: 1778-86. PMID 18001057 DOI: 10.1021/tx700207u  0.56
2004 Hummel MA, Dickmann LJ, Rettie AE, Haining RL, Tracy TS. Differential activation of CYP2C9 variants by dapsone. Biochemical Pharmacology. 67: 1831-41. PMID 15130760 DOI: 10.1016/j.bcp.2004.01.017  0.56
2004 Redman AR, Dickmann LJ, Kidd RS, Goldstein JA, Ritchie DM, Hon YY. CYP2C9 genetic polymorphisms and warfarin. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 10: 149-54. PMID 15094935 DOI: 10.1177/107602960401000205  0.56
2004 Dickmann LJ, Locuson CW, Jones JP, Rettie AE. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Molecular Pharmacology. 65: 842-50. PMID 15044613 DOI: 10.1124/mol.65.4.842  0.56
2002 Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 385-90. PMID 11901091 DOI: 10.1124/dmd.30.4.385  0.56
2001 Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Molecular Pharmacology. 60: 382-7. PMID 11455026  0.56
2001 Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. Journal of Clinical Pharmacology. 41: 715-22. PMID 11452703 DOI: 10.1177/00912700122010618  0.56
1996 Hrabak EM, Dickmann LJ, Satterlee JS, Sussman MR. Characterization of eight new members of the calmodulin-like domain protein kinase gene family from Arabidopsis thaliana. Plant Molecular Biology. 31: 405-12. PMID 8756605  0.56
Show low-probability matches.